Clopidogrel Platelet Function Tests
Caveats and Controversies
New P2Y12 antagonists have recently been introduced. Two years ago prasugrel was FDA approved and in July 2011, ticagrelor was FDA approved as well. Ticagrelor is the first direct antagonist, meaning that it does not require metabolism by the liver to become active as the prodrugs ticlopidine, clopidogrel and prasugrel do to form an active metabolite. Ticagrelor is also the first reversible P2Y12 antagonist. Other antagonists which can be given intravenously are now under investigation.
Jump to section:
- Learning Objectives
- Platelet Function Tests for the Detection of Clopidogrel Resistance1
- Platelet Function Tests for the Detection of Clopidogrel Resistance
- Caveat: There Is No Perfect Platelet Function Test...
- Problems With Testing For Clopidogrel
- How We Choose a Testing Method
- Methodology Table
- Platelet Function Testing Available at Mayo Clinic Florida
- Light Transmission Platelet Aggregometry Studies (LTA)
- Platelet Aggregation (Cont'd)
- Normal Patient
- Accumetrics VerifyNow Test
- VerifyNow P2Y12 Test
- P2Y12 Test Interferences
- P2Y12 Antagonists2
- Can These Platelet Function Tests Be Used for Ticagrelor (Brilinta/Brilique)?
- PFA–100 (Cont'd)
- INNOVANCE PFA P2Y
- TEG — Platelet Mapping
- Results of VerifyNow Testing
- 2009–2011 Clopidogrel Response at 30%
- Genetic Testing: Clopidogrel Metabolism
- Clopidogrel Metabolism
- Number of Gene Polymorphisms
- Clopidogrel Metabolism and Genetic Polymorphisms
- Why Do Genetic Testing?
- Clopidogrel Genetics (Cont'd)
- Caveats — Other Reasons for Poor Response to Clopidogrel
- CYP2C19 Polymorphism May Require Another Factor
- Controversy for Clopidogrel
- Warning: Diminished Effectiveness In Poor Metabolizers
- What Does Warning Mean For Clinicians With Patients On Clopidogrel?
- FDA Answer
- More Questions